Conjugate Vaccines Market Insights, Forecast to 2025


Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or the antigen attached or conjugated to a protein.

This protein has a key role in enhancing the immunogenic property of the polysaccharide. These vaccines are mainly used to immunize infants and children against invasive disease caused by Hib bacteria, H. influenzae, Streptococcus pneumoniae, and Neisseria meningitidis.

The increase in use of conjugate vaccines for adults, rise in number of regulatory approvals for conjugate vaccines, growth in prevalence of diseases caused by microorganisms such as Streptococcus pneumoniae and Neisseria meningitidis, and technological advancements majorly drive the growth of the market. In contrast, low accessibility to vaccines in remote areas and complex production procedure of conjugate vaccine restraint the market growth.

The global Conjugate Vaccines market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Conjugate Vaccines market based on company, product type, end user and key regions.

This report studies the global market size of Conjugate Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Conjugate Vaccines in these regions.

This research report categorizes the global Conjugate Vaccines market by top players/brands, region, type and end user. This report also studies the global Conjugate Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

  • Novartis
  • Neuron Biotech
  • Serum Institute of India
  • Pfizer
  • Sanofi Pasteur
  • Bharat Biotech
  • Biological
  • GlaxoSmithKline
  • Merck
  • CSL

Market size by Product 

  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines
  • By disease indication
  • Pneumococcal
  • Influenza
  • Diphtheria Tetanus and Pertussis (DTP)
  • Meningococcal
  • Others

By type

  • By pathogen type
  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combination (Viral and Bacterial) Conjugate Vaccine
  • Market size by End User
  • Pediatrics
  • Adults

Market size by Region

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Singapore
  • Malaysia
  • Philippines
  • Thailand
  • Vietnam
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Central & South America
  • Brazil
  • Rest of Central & South America
  • Middle East & Africa
  • GCC Countries
  • Turkey
  • Egypt
  • South Africa

The study objectives of this report are:

  • To study and analyze the global Conjugate Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
  • To understand the structure of Conjugate Vaccines market by identifying its various subsegments.
  • To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
  • Focuses on the key global Conjugate Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
  • To project the value and sales volume of Conjugate Vaccines submarkets, with respect to key regions.
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Conjugate Vaccines are as follows:

  • History Year: 2014-2018
  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Conjugate Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of content

1 Study Coverage
1.1 Conjugate Vaccines Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Conjugate Vaccines Market Size Growth Rate by Product
1.4.2 Monovalent Conjugate Vaccines
1.4.3 Multivalent Conjugate Vaccines
1.5 Market by End User
1.5.1 Global Conjugate Vaccines Market Size Growth Rate by End User
1.5.2 Pediatrics
1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Conjugate Vaccines Market Size
2.1.1 Global Conjugate Vaccines Revenue 2014-2025
2.1.2 Global Conjugate Vaccines Sales 2014-2025
2.2 Conjugate Vaccines Growth Rate by Regions
2.2.1 Global Conjugate Vaccines Sales by Regions
2.2.2 Global Conjugate Vaccines Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Conjugate Vaccines Sales by Manufacturers
3.1.1 Conjugate Vaccines Sales by Manufacturers
3.1.2 Conjugate Vaccines Sales Market Share by Manufacturers
3.1.3 Global Conjugate Vaccines Market Concentration Ratio (CR5 and HHI)
3.2 Conjugate Vaccines Revenue by Manufacturers
3.2.1 Conjugate Vaccines Revenue by Manufacturers (2014-2019)
3.2.2 Conjugate Vaccines Revenue Share by Manufacturers (2014-2019)
3.3 Conjugate Vaccines Price by Manufacturers
3.4 Conjugate Vaccines Manufacturing Base Distribution, Prod

276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414

Follow Us On linkedin :


Please enter your comment!
Please enter your name here